Literature DB >> 11315236

DXA of the hip and heel ultrasound but not densitometry of the fingers can discriminate female hip fracture patients from controls: a comparison between four different methods.

A Ekman1, K Michaëlsson, M Petrén-Mallmin, S Ljunghall, H Mallmin.   

Abstract

Dual-energy X-ray absorptiometry (DXA) of the proximal femur and in more recent years quantitative ultrasound (QUS) of the heel are the most established methods for assessing hip fracture risk. Measurement of the fingers offers a new approach. We performed DXA of the proximal femur, QUS of the heel and fingers, and radiographic absorptiometry (RA) of the fingers in 87 non-institutionalized women, 65-85 years of age, with a first hip fracture and compared them with 195 randomly selected age-matched controls. Bone mineral density (BMD) of the femoral neck and heel Stiffness Index were significantly lower among cases than among controls (by 15% and 17%, respectively; p < 0.0001), whereas no significant differences were found for finger measurements. When applying the WHO criterion of osteoporosis, 62-98% of the patients were classified as osteoporotic, compared with 19-85% of the controls, depending on method and site. The risks of hip fracture, estimated as odds ratios for every 1 SD reduction in femoral neck BMD, heel Stiffness Index, finger QUS and finger RA, were: 3.6 (95% CI 2.4-5.5), 3.4 (95% CI 2.2-5.0), 1.0 (95% CI 0.7-1.3) and 1.2 (95% CI 0.8-1.6), respectively. Compared with women with normal BMD of the femoral neck, those classified as osteopenic had an odds ratio of hip fracture of 14 (95% CI 2-110), whereas those classified as osteoporotic had an odds ratio of 63 (95% CI 8-501). We conclude that hip DXA and heel QUS have similar capacities to discriminate the risk of a first hip fracture, whereas QUS and RA of the phalanges seem inferior techniques for differentiating female hip fracture patients from controls.

Entities:  

Mesh:

Year:  2001        PMID: 11315236     DOI: 10.1007/s001980170128

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  7 in total

1.  Quantitative ultrasound of the heel and fracture risk assessment: an updated meta-analysis.

Authors:  A Moayyeri; J E Adams; R A Adler; M-A Krieg; D Hans; J Compston; E M Lewiecki
Journal:  Osteoporos Int       Date:  2011-10-27       Impact factor: 4.507

2.  Evaluation of bone density in infancy and adolescence. Review of medical literature and personal experience.

Authors:  Luisella Pedrotti; Barbara Bertani; Gabriella Tuvo; Francesca Barone; Ilaria Crivellari; Stefano Lucanto; Mora Redento
Journal:  Clin Cases Miner Bone Metab       Date:  2010-05

3.  Comparison between the Klemetti index and heel DXA BMD measurements in the diagnosis of reduced skeletal bone mineral density in the elderly.

Authors:  Anders Halling; G Rutger Persson; Johan Berglund; Owe Johansson; Stefan Renvert
Journal:  Osteoporos Int       Date:  2004-12-17       Impact factor: 4.507

4.  Ten-year probabilities of clinical vertebral fractures according to phalangeal quantitative ultrasonography.

Authors:  J A Kanis; O Johnell; A Oden; C De Laet; F de Terlizzi
Journal:  Osteoporos Int       Date:  2004-12-07       Impact factor: 4.507

Review 5.  Quantitative ultrasound: use in the detection of fractures and in the assessment of bone composition.

Authors:  Claus-C Glüer; Reinhard Barkmann
Journal:  Curr Osteoporos Rep       Date:  2003-12       Impact factor: 5.096

6.  Quantitative Ultrasound (QUS) in the Management of Osteoporosis and Assessment of Fracture Risk: An Update.

Authors:  Didier Hans; Antoine Métrailler; Elena Gonzalez Rodriguez; Olivier Lamy; Enisa Shevroja
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

7.  Early menopause and weight loss are significant factors associated with risk of future fracture in middle-aged women.

Authors:  Louise Moberg; Viktor Hamrefors; Artur Fedorowski; Cecilia Rogmark
Journal:  BMC Musculoskelet Disord       Date:  2022-08-16       Impact factor: 2.562

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.